Case ReportPublished 12 October 2026Case Report: From unresectable to resectable: successful conversion therapy with TACE, HAIC, envafolimab, and olaparib in advanced intrahepatic cholangiocarcinomaChi Ma · Kun Feng · Jun ZhouFrontiers in Oncologydoi 10.3389/fonc.2026.1935499
ReviewPublished 9 October 2026Prostate cancer: advancements in targeted therapiesIlesha Ewart · Manreet RandhawaFrontiers in Endocrinologydoi 10.3389/fendo.2026.1924299
ReviewPublished 31 July 2026Circulating tumour DNA in mCRPC: bridging tumour biology and real-time treatment monitoringChimbabantu Kaoma · Mike Sathekge · Joseph Chalwe · Kgomotso Mokoala · Mankgopo KgatleFrontiers in Molecular Medicinedoi 10.3389/fmmed.2026.1852641
ReviewPublished 28 July 2026Advancing the frontiers of ovarian cancer therapy: a comprehensive synthesis of emerging cell death paradigmsXi Ye · Weiping Zhu · Xiaojie Sun · Fangqiumei Yu · Qinhong Shen · Yingao Zheng · Xuanxuan Hong · Le Yu · Hanwen Zhang · Xiangfeng Zhang · Liehong WangOncology Reviewsdoi 10.3389/or.2026.1850292
ReviewPublished 15 July 2026PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencingNatalia Gierulska · Nina Jankowska · Adrianna Kwiatkowska · Piotr Kuchno · Kinga Łysak · Katarzyna Szklener · Kamil Kośmider · Magdalena SkórzewskaOncology Reviewsdoi 10.3389/or.2026.1834484
ReviewPublished 9 July 2026Targeting glucocorticoid receptor signaling in platinum-resistant ovarian cancer: translational rationale and clinical advances following the ROSELLA trialWenxiang Wang · Zhanghuan Li · Junjie Zhao · Mengyuan Chang · Yafang Zhang · Xiangyi Shen · Junming Yue · John Schorge · Wenjing ZhangOncology Reviewsdoi 10.3389/or.2026.1861081
Systematic ReviewPublished 9 July 2026Comparative efficacy of subsequent-line therapies for advanced triple-negative breast cancer: a bayesian network meta-analysisZheng Xu · Linxian Ding · Tai Zhao · Zhoumin XuOncology Reviewsdoi 10.3389/or.2026.1834466
Original ResearchPublished 13 November 2025Comprehensive genomic profiling for homologous recombination deficiency guides PARP inhibitor therapy recommendations in ovarian cancerAlp Inci · Isabell Witzel · Holger Moch · Sepehr Rahmani-Khajouei · Martin Zoche · Eleftherios Pierre SamartzisPathology and Oncology Researchdoi 10.3389/pore.2025.1612266
Natural ProductsPublished 22 August 2025A review on integrative approaches in oncology: bridging ayurvedic medicine and modern cancer therapeuticsSudhanshu Kumar Jha · Neha Singh · Ozasvi R. Shanker · Ishika Antil · Jaydeep Singh Baghel · Vittal Huddar · Richa TripathiFrontiers in Natural Productsdoi 10.3389/fntpr.2025.1635197
